Search...
Praxis Precision Medicines rises 30% to a 3-year high after halting epilepsy study early for strong results.
Shares of Praxis Precision Medicines soared on Friday after the company decided to end an epilepsy study ahead of schedule due to significant effectiveness. The stock surged 30%, reaching a new three-year high, following this unexpected success in the epilepsy treatment.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments